# Eli Lilly and Company

Type: Company (LLY)

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/eli-lilly-and-company
Canonical HTML page: https://getlegalbrief.com/entity/eli-lilly-and-company

## Timeline

- **2026-07-21**: Lawsuit Filed — Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
- **2026-03-13**: Impurity Warning — Lilly issues formal warning after testing reveals impurities in compounded samples.
- **2026-03**: FDA Approves Wegovy 7.2 mg — Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
- **2024-Q1**: Compounding Surge — Shortage status triggers Section 503B exemptions, allowing pharmacies to mass-produce compounded versions.
- **2023-11-08**: Zepbound Approval — Tirzepatide approved for chronic weight management, exacerbating supply shortages.
- **2022-05-13**: Mounjaro FDA Approval — FDA approves tirzepatide for type 2 diabetes, leading to immediate high demand.

## Recent coverage (2 stories)

### Novo Sues Lilly: Omits Wegovy’s 19% Weight Loss, Seeks Injunction
2026-07-21 14:14:08 · Sentiment: Neutral · Impact: 7/10 · Sources: 3

Novo Nordisk alleges Lanham Act violations; case tests whether outdated comparisons in DTC ads constitute false advertising, with potential precedent for pharma.
Full story: https://getlegalbrief.com/story/novo-sues-lilly-false-advertising-glp1-injunction

### Lilly Flags Impurities in Compounded GLP-1s, Escalating Regulatory Battle
2026-03-13 20:18:29 · Sentiment: Negative · Impact: 7/10 · Sources: 23

Eli Lilly has issued a formal warning regarding discovered impurities in compounded versions of its blockbuster weight-loss medication, tirzepatide. This development marks a significant escalation in the ongoing regulatory and legal conflict between pharmaceutical giants and the compounding industry over safety standards and patent enforcement.
Full story: https://getlegalbrief.com/story/lilly-tirzepatide-compounding-impurity-warning

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.